Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
iShares U.S. Pharmaceutical ETF
(NY:
IHE
)
101.99
+1.35 (+1.34%)
Official Closing Price
Updated: 6:30 PM EDT, Jul 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,442,982
Open
100.12
Bid (Size)
102.00 (200)
Ask (Size)
102.38 (500)
Prev. Close
100.64
Today's Range
99.68 - 102.65
52wk Range
64.94 - 103.70
Shares Outstanding
82,000
Dividend Yield
1.12%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?
↗
July 22, 2026
IHE delivered stronger 5-year returns, but VHT's 0.09% expense ratio and 411 holdings offer broader diversification at lower cost.
Via
The Motley Fool
Topics
ETFs
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
↗
July 19, 2026
BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.
Via
The Motley Fool
Topics
ETFs
Performance
YTD
+20.2%
+20.2%
1 Month
+10.1%
+10.1%
3 Month
+17.4%
+17.4%
6 Month
+17.1%
+17.1%
1 Year
+49.9%
+49.9%
More News
Read More
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?
↗
July 18, 2026
Via
The Motley Fool
Topics
ETFs
KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show?
↗
January 30, 2026
Via
Stocktwits
Why Did NRXP Stock Surge 21% Pre-Market Today?
↗
January 14, 2026
Via
Stocktwits
White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report
↗
September 26, 2025
Via
Stocktwits
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?
↗
July 16, 2026
Via
The Motley Fool
Topics
ETFs
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy?
↗
July 10, 2026
Via
The Motley Fool
Topics
ETFs
IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?
↗
July 05, 2026
Via
The Motley Fool
Topics
ETFs
Intellectual Property
Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors?
↗
June 17, 2026
Via
The Motley Fool
Topics
ETFs
iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns
↗
June 10, 2026
Via
The Motley Fool
Topics
ETFs
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
↗
May 27, 2026
Via
The Motley Fool
Topics
ETFs
FDA Vaccine Chief Vinay Prasad To Exit Agency In April: Report
↗
March 06, 2026
Via
Stocktwits
TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint
↗
March 03, 2026
Via
Stocktwits
Topics
Workforce
FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development
↗
February 18, 2026
Via
Stocktwits
Topics
ETFs
Government
Why Did IINN Stock Surge 28% In Pre-Market Today?
↗
February 09, 2026
Via
Stocktwits
HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling?
↗
February 05, 2026
Via
Stocktwits
Topics
Intellectual Property
LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook
↗
February 04, 2026
Via
Stocktwits
US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report
↗
December 01, 2025
Via
Stocktwits
Topics
World Trade
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs
↗
November 15, 2025
Via
Benzinga
Topics
ETFs
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
↗
November 12, 2025
Via
Benzinga
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
↗
October 30, 2025
Via
Benzinga
Topics
ETFs
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
↗
September 29, 2025
Via
Benzinga
Topics
ETFs
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
↗
September 29, 2025
Via
Benzinga
Topics
Government
World Trade
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
↗
September 08, 2025
Via
Benzinga
Frequently Asked Questions
Is iShares U.S. Pharmaceutical ETF publicly traded?
Yes, iShares U.S. Pharmaceutical ETF is publicly traded.
What exchange does iShares U.S. Pharmaceutical ETF trade on?
iShares U.S. Pharmaceutical ETF trades on the New York Stock Exchange
What is the ticker symbol for iShares U.S. Pharmaceutical ETF?
The ticker symbol for iShares U.S. Pharmaceutical ETF is IHE on the New York Stock Exchange
What is the current price of iShares U.S. Pharmaceutical ETF?
The current price of iShares U.S. Pharmaceutical ETF is 101.99
When was iShares U.S. Pharmaceutical ETF last traded?
The last trade of iShares U.S. Pharmaceutical ETF was at 07/23/26 06:30 PM ET
What is the market capitalization of iShares U.S. Pharmaceutical ETF?
The market capitalization of iShares U.S. Pharmaceutical ETF is 8.36M
How many shares of iShares U.S. Pharmaceutical ETF are outstanding?
iShares U.S. Pharmaceutical ETF has 8M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.